User login
But a new report finds that officials are concerned about possible fraud and patient safety risks from products made at nearly a quarter of the pharmacies that fill the bulk of those prescriptions.
“Although some of this billing may be legitimate, all of these pharmacies warrant further scrutiny,” concludes the report from the Office of Inspector General for the Department of Health and Human Services.
In total, 547 pharmacies – nearly 23% of those that submit most of the bills to Medicare for making these creams – hit one or more of five red-flag markers set by investigators. Those included what the researchers called “extremely high” prices; large percentages of Medicare members getting identical drugs – 16 of the pharmacies billed for identical drugs for 200 or more customers; “greatly increased” year-over-year billing – 20 pharmacies increased their billing by more than 10,000%; or having a single medical provider writing more than 131 prescriptions. More than half of those pharmacies hit two or more measures – and 10 hit all five.
One Oregon pharmacy, for example, submitted claims for 91% of its customers. A pharmacy in New York submitted 5,342 prescriptions ordered by one podiatrist, while a Florida pharmacy saw its Medicare billing for such treatments go from $7,468 in 2015 to $1.8 million the following year.
Many of the pharmacies are clustered in four cities: Detroit, Houston, Los Angeles, and New York.
The report comes amid ongoing concern by Medicare officials about compounded drugs. In addition to questions like those raised in the report about overuse and pricing, safety has been a key issue in recent years. A meningitis outbreak in 2012 was linked to a Massachusetts pharmacy that did not maintain sterile conditions and sold tainted made-to-order injections that killed 64 Americans.
When done safely, pharmacy-made compounded drugs provide a legitimate option for patients whose medical needs can’t be met by commercially available products mass-produced by pharmaceutical companies. For example, a patient who can’t swallow a commercially available prescription pill might get a liquid version of a drug.
State boards of pharmacy generally oversee compounding pharmacies, and the drugs they produce are not considered approved by the Food and Drug Administration.
The new report focuses on concerns with compounded topical medications.
Medicare spending for such treatments has skyrocketed, rising more than 2,350%, from $13.2 million in 2010 to $323.5 million in 2016. Price hikes and an increase in the number of prescriptions written drove the increase, the report said.
It is not the first time the inspector general has looked at compounded drugs. A 2016 report found that overall spending on all types of compounded drugs – not just topical medications – rose sharply. The U.S. Postal Service inspector general and the Department of Defense also have raised concerns about rising spending and possible fraud for compounded drugs.
In response to those previous reports, the International Academy of Compounding Pharmacists, the industry’s trade group, has said that legitimately compounded drugs “can dramatically improve a patient’s quality of life,” noting that proper billing controls need to be in place. The inspector general’s report in 2016, it added, found that “such controls are not in place.”
This report, which the compounding trade group has not yet reviewed, focuses on topical drugs and a subset of the 15,290 pharmacies that provide at least one such prescription each year. It looked at billing records from the 2,388 pharmacies that do at least 10 such prescriptions a year – providing 93% of all compounded topical drugs paid for by Medicare.
Most of the prescriptions were for pain treatment, made from ingredients such as lidocaine or diclofenac sodium.
On average, those compounds were more expensive than noncompounded drugs with the same ingredients.
For example, Medicare paid an average of $751 per tube of compounded lidocaine, and $1,506 for the diclofenac, according to the inspector general’s report. Noncompounded tubes of those drugs averaged $445 and $128, respectively.
FDA Commissioner Scott Gottlieb, MD, recently outlined new efforts his agency is taking to oversee compounded drugs in the wake of legislation passed by Congress following the meningitis outbreak.
“The FDA is inspecting compounding facilities to assess whether drugs that are essentially copies of FDA-approved drugs are being compounded for patients” who could otherwise take a product sold commercially, he said in a statement issued on June 28.
Dr. Gottlieb also said the FDA plans to make more information available to patients and their doctors about compounded topical pain creams, including information about their effectiveness and any potential safety risks.
Not being effective is a safety risk, noted Miriam Anderson, a researcher with the inspector general’s office who helped write the report.
The report urged the Centers for Medicare & Medicaid Services to clarify some of its policies to emphasize that insurers can limit the use of compounded drugs by requiring prior authorization or other steps. The agency concurred with the recommendations, according to the report, including the need to “follow up on pharmacies with questionable Part D billing and the prescribers associated with these pharmacies.”
Ms. Anderson said the inspector general’s office is continuing to probe the issue.
“We will investigate a number of leads on specific pharmacies and prescribers who were identified as having these questionable patterns,” she said. “Whenever we see that kind of increase in spending, it raises concern about fraud, waste, and abuse.”
KHN’s coverage of prescription drug development, costs, and pricing is supported in part by the Laura and John Arnold Foundation.
Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.
But a new report finds that officials are concerned about possible fraud and patient safety risks from products made at nearly a quarter of the pharmacies that fill the bulk of those prescriptions.
“Although some of this billing may be legitimate, all of these pharmacies warrant further scrutiny,” concludes the report from the Office of Inspector General for the Department of Health and Human Services.
In total, 547 pharmacies – nearly 23% of those that submit most of the bills to Medicare for making these creams – hit one or more of five red-flag markers set by investigators. Those included what the researchers called “extremely high” prices; large percentages of Medicare members getting identical drugs – 16 of the pharmacies billed for identical drugs for 200 or more customers; “greatly increased” year-over-year billing – 20 pharmacies increased their billing by more than 10,000%; or having a single medical provider writing more than 131 prescriptions. More than half of those pharmacies hit two or more measures – and 10 hit all five.
One Oregon pharmacy, for example, submitted claims for 91% of its customers. A pharmacy in New York submitted 5,342 prescriptions ordered by one podiatrist, while a Florida pharmacy saw its Medicare billing for such treatments go from $7,468 in 2015 to $1.8 million the following year.
Many of the pharmacies are clustered in four cities: Detroit, Houston, Los Angeles, and New York.
The report comes amid ongoing concern by Medicare officials about compounded drugs. In addition to questions like those raised in the report about overuse and pricing, safety has been a key issue in recent years. A meningitis outbreak in 2012 was linked to a Massachusetts pharmacy that did not maintain sterile conditions and sold tainted made-to-order injections that killed 64 Americans.
When done safely, pharmacy-made compounded drugs provide a legitimate option for patients whose medical needs can’t be met by commercially available products mass-produced by pharmaceutical companies. For example, a patient who can’t swallow a commercially available prescription pill might get a liquid version of a drug.
State boards of pharmacy generally oversee compounding pharmacies, and the drugs they produce are not considered approved by the Food and Drug Administration.
The new report focuses on concerns with compounded topical medications.
Medicare spending for such treatments has skyrocketed, rising more than 2,350%, from $13.2 million in 2010 to $323.5 million in 2016. Price hikes and an increase in the number of prescriptions written drove the increase, the report said.
It is not the first time the inspector general has looked at compounded drugs. A 2016 report found that overall spending on all types of compounded drugs – not just topical medications – rose sharply. The U.S. Postal Service inspector general and the Department of Defense also have raised concerns about rising spending and possible fraud for compounded drugs.
In response to those previous reports, the International Academy of Compounding Pharmacists, the industry’s trade group, has said that legitimately compounded drugs “can dramatically improve a patient’s quality of life,” noting that proper billing controls need to be in place. The inspector general’s report in 2016, it added, found that “such controls are not in place.”
This report, which the compounding trade group has not yet reviewed, focuses on topical drugs and a subset of the 15,290 pharmacies that provide at least one such prescription each year. It looked at billing records from the 2,388 pharmacies that do at least 10 such prescriptions a year – providing 93% of all compounded topical drugs paid for by Medicare.
Most of the prescriptions were for pain treatment, made from ingredients such as lidocaine or diclofenac sodium.
On average, those compounds were more expensive than noncompounded drugs with the same ingredients.
For example, Medicare paid an average of $751 per tube of compounded lidocaine, and $1,506 for the diclofenac, according to the inspector general’s report. Noncompounded tubes of those drugs averaged $445 and $128, respectively.
FDA Commissioner Scott Gottlieb, MD, recently outlined new efforts his agency is taking to oversee compounded drugs in the wake of legislation passed by Congress following the meningitis outbreak.
“The FDA is inspecting compounding facilities to assess whether drugs that are essentially copies of FDA-approved drugs are being compounded for patients” who could otherwise take a product sold commercially, he said in a statement issued on June 28.
Dr. Gottlieb also said the FDA plans to make more information available to patients and their doctors about compounded topical pain creams, including information about their effectiveness and any potential safety risks.
Not being effective is a safety risk, noted Miriam Anderson, a researcher with the inspector general’s office who helped write the report.
The report urged the Centers for Medicare & Medicaid Services to clarify some of its policies to emphasize that insurers can limit the use of compounded drugs by requiring prior authorization or other steps. The agency concurred with the recommendations, according to the report, including the need to “follow up on pharmacies with questionable Part D billing and the prescribers associated with these pharmacies.”
Ms. Anderson said the inspector general’s office is continuing to probe the issue.
“We will investigate a number of leads on specific pharmacies and prescribers who were identified as having these questionable patterns,” she said. “Whenever we see that kind of increase in spending, it raises concern about fraud, waste, and abuse.”
KHN’s coverage of prescription drug development, costs, and pricing is supported in part by the Laura and John Arnold Foundation.
Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.
But a new report finds that officials are concerned about possible fraud and patient safety risks from products made at nearly a quarter of the pharmacies that fill the bulk of those prescriptions.
“Although some of this billing may be legitimate, all of these pharmacies warrant further scrutiny,” concludes the report from the Office of Inspector General for the Department of Health and Human Services.
In total, 547 pharmacies – nearly 23% of those that submit most of the bills to Medicare for making these creams – hit one or more of five red-flag markers set by investigators. Those included what the researchers called “extremely high” prices; large percentages of Medicare members getting identical drugs – 16 of the pharmacies billed for identical drugs for 200 or more customers; “greatly increased” year-over-year billing – 20 pharmacies increased their billing by more than 10,000%; or having a single medical provider writing more than 131 prescriptions. More than half of those pharmacies hit two or more measures – and 10 hit all five.
One Oregon pharmacy, for example, submitted claims for 91% of its customers. A pharmacy in New York submitted 5,342 prescriptions ordered by one podiatrist, while a Florida pharmacy saw its Medicare billing for such treatments go from $7,468 in 2015 to $1.8 million the following year.
Many of the pharmacies are clustered in four cities: Detroit, Houston, Los Angeles, and New York.
The report comes amid ongoing concern by Medicare officials about compounded drugs. In addition to questions like those raised in the report about overuse and pricing, safety has been a key issue in recent years. A meningitis outbreak in 2012 was linked to a Massachusetts pharmacy that did not maintain sterile conditions and sold tainted made-to-order injections that killed 64 Americans.
When done safely, pharmacy-made compounded drugs provide a legitimate option for patients whose medical needs can’t be met by commercially available products mass-produced by pharmaceutical companies. For example, a patient who can’t swallow a commercially available prescription pill might get a liquid version of a drug.
State boards of pharmacy generally oversee compounding pharmacies, and the drugs they produce are not considered approved by the Food and Drug Administration.
The new report focuses on concerns with compounded topical medications.
Medicare spending for such treatments has skyrocketed, rising more than 2,350%, from $13.2 million in 2010 to $323.5 million in 2016. Price hikes and an increase in the number of prescriptions written drove the increase, the report said.
It is not the first time the inspector general has looked at compounded drugs. A 2016 report found that overall spending on all types of compounded drugs – not just topical medications – rose sharply. The U.S. Postal Service inspector general and the Department of Defense also have raised concerns about rising spending and possible fraud for compounded drugs.
In response to those previous reports, the International Academy of Compounding Pharmacists, the industry’s trade group, has said that legitimately compounded drugs “can dramatically improve a patient’s quality of life,” noting that proper billing controls need to be in place. The inspector general’s report in 2016, it added, found that “such controls are not in place.”
This report, which the compounding trade group has not yet reviewed, focuses on topical drugs and a subset of the 15,290 pharmacies that provide at least one such prescription each year. It looked at billing records from the 2,388 pharmacies that do at least 10 such prescriptions a year – providing 93% of all compounded topical drugs paid for by Medicare.
Most of the prescriptions were for pain treatment, made from ingredients such as lidocaine or diclofenac sodium.
On average, those compounds were more expensive than noncompounded drugs with the same ingredients.
For example, Medicare paid an average of $751 per tube of compounded lidocaine, and $1,506 for the diclofenac, according to the inspector general’s report. Noncompounded tubes of those drugs averaged $445 and $128, respectively.
FDA Commissioner Scott Gottlieb, MD, recently outlined new efforts his agency is taking to oversee compounded drugs in the wake of legislation passed by Congress following the meningitis outbreak.
“The FDA is inspecting compounding facilities to assess whether drugs that are essentially copies of FDA-approved drugs are being compounded for patients” who could otherwise take a product sold commercially, he said in a statement issued on June 28.
Dr. Gottlieb also said the FDA plans to make more information available to patients and their doctors about compounded topical pain creams, including information about their effectiveness and any potential safety risks.
Not being effective is a safety risk, noted Miriam Anderson, a researcher with the inspector general’s office who helped write the report.
The report urged the Centers for Medicare & Medicaid Services to clarify some of its policies to emphasize that insurers can limit the use of compounded drugs by requiring prior authorization or other steps. The agency concurred with the recommendations, according to the report, including the need to “follow up on pharmacies with questionable Part D billing and the prescribers associated with these pharmacies.”
Ms. Anderson said the inspector general’s office is continuing to probe the issue.
“We will investigate a number of leads on specific pharmacies and prescribers who were identified as having these questionable patterns,” she said. “Whenever we see that kind of increase in spending, it raises concern about fraud, waste, and abuse.”
KHN’s coverage of prescription drug development, costs, and pricing is supported in part by the Laura and John Arnold Foundation.
Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.